Literature DB >> 3087210

Treatment of severe androgen excess due to ovarian hyperthecosis with a long-acting gonadotropin-releasing hormone agonist.

K A Steingold, H L Judd, R K Nieberg, J K Lu, R J Chang.   

Abstract

A 31-year-old nulligravid patient presented with irregular menses, severe hirsutism, and infertility. Evaluation revealed marked increases of serum androstenedione and testosterone levels and a possible ovarian mass. At operation a cystic teratoma was removed from the left ovary and bilateral wedge resection revealed severe ovarian hyperthecosis. After operation only a transient decrease of androstenedione and testosterone was noted and the patient failed to ovulate or improve clinically. Subsequently a long-acting gonadotropin-releasing hormone agonist was administered daily for 6 months, which reduced circulating delta 4-steroids and estrogens to levels approximating those of castrated women. Immediately after discontinuation of treatment, ovulation induction was successfully achieved with human menopausal gonadotropin. This report introduces a new therapeutic approach to the problem of severe ovarian hyperthecosis and may provide an opportunity for childbearing in these patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3087210     DOI: 10.1016/0002-9378(86)90706-4

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  5 in total

1.  Postmenopausal virilization in a woman with gonadotropin dependent ovarian hyperthecosis.

Authors:  C Manieri; C Di Bisceglie; R Fornengo; T Grosso; E Zumpano; F Calvo; E Berardengo; M Volante; M Papotti
Journal:  J Endocrinol Invest       Date:  1998-02       Impact factor: 4.256

2.  Polycystic ovary syndrome: an enigma awaiting solution.

Authors:  M Schwartz; P R Gindoff; R Jewelewicz
Journal:  Bull N Y Acad Med       Date:  1987-03

3.  A virilizing Leydig cell tumor of the ovary associated with stromal hyperplasia under gonadotropin control.

Authors:  J A Marcondes; M Nery; B B Mendonça; S A Hayashida; H W Halbe; F M Carvalho; B L Wajchenberg
Journal:  J Endocrinol Invest       Date:  1997-12       Impact factor: 4.256

Review 4.  GnRH agonists and antagonists. Current clinical status.

Authors:  M Filicori; C Flamigni
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

5.  Diagnostic Challenges in Ovarian Hyperthecosis: Clinical Presentation with Subdiagnostic Testosterone Levels.

Authors:  Sanket Shah; Callie Torres; Naser Gharaibeh
Journal:  Case Rep Endocrinol       Date:  2022-01-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.